First human tests begin for new kidney disease drug
NCT ID NCT06209177
Summary
This is an early-stage study to test the safety and effects of a new drug called ARO-CFB. It involves healthy volunteers and patients with kidney diseases caused by an overactive part of the immune system, like IgA Nephropathy. The main goal is to see how the body handles the drug and to check for any side effects before testing if it can help control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Auckland, 1010, New Zealand
Conditions
Explore the condition pages connected to this study.